Utilizing Combination Therapies Targeting Diverse TGF-β-Dependent Anti- Fibrotic & Immunosuppressive Mechanisms in Oncology
Time: 12:00 pm
day: Conference Day One
Details:
- Refocusing from mono-directed TGF-β therapies to combination treatments for novel and effective anti-cancer therapies
- Exploring alternatives to checkpoint inhibitors for novel combination therapies using TGF-β targeted therapies
- Deep diving into ALK5 inhibitors in conjunction with autotaxin inhibitors to show clinical efficacy
New Data!
